$2.08
0.96%
Downside
Day's Volatility :4.19%
Upside
3.26%
12.5%
Downside
52 Weeks Volatility :59.1%
Upside
53.26%
Period | Cellectar Biosciences Inc | Index (Russel 2000) |
---|---|---|
3 Months | -37.54% | 0.0% |
6 Months | -48.89% | 0.0% |
1 Year | -9.57% | 0.0% |
3 Years | -80.0% | -22.3% |
Market Capitalization | 75.1M |
Book Value | $0.27 |
Earnings Per Share (EPS) | -3.09 |
PEG Ratio | 0.0 |
Wall Street Target Price | 12.6 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -91.47% |
Return On Equity TTM | -304.38% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -42.0M |
Diluted Eps TTM | -3.09 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.91 |
EPS Estimate Next Year | -2.83 |
EPS Estimate Current Quarter | -1.0 |
EPS Estimate Next Quarter | 0.0 |
What analysts predicted
Upside of 505.77%
Sell
Neutral
Buy
Cellectar Biosciences Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Cellectar Biosciences Inc | 9.47% | -48.89% | -9.57% | -80.0% | -90.84% |
![]() Regeneron Pharmaceuticals, Inc. | 5.97% | 16.25% | 37.11% | 69.18% | 305.56% |
![]() Novo Nordisk A/s | 9.99% | -3.52% | 34.24% | 158.74% | 417.73% |
![]() Alnylam Pharmaceuticals, Inc. | -5.15% | 64.67% | 22.72% | 31.08% | 198.44% |
![]() Vertex Pharmaceuticals Incorporated | 0.45% | 14.0% | 36.06% | 143.5% | 167.72% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Cellectar Biosciences Inc | NA | NA | 0.0 | -3.91 | -3.04 | -0.91 | NA | 0.27 |
![]() Regeneron Pharmaceuticals, Inc. | 29.93 | 29.93 | 1.54 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
![]() Novo Nordisk A/s | 44.01 | 44.01 | 1.98 | 3.44 | 0.89 | 0.23 | 0.01 | 25.24 |
![]() Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.55 | -15.01 | 0.02 | NA | -0.02 |
![]() Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.57 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Cellectar Biosciences Inc | Buy | $75.1M | -90.84% | NA | 0.0% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $124.7B | 305.56% | 29.93 | 32.04% |
![]() Novo Nordisk A/s | Buy | $585.3B | 417.73% | 44.01 | 34.84% |
![]() Alnylam Pharmaceuticals, Inc. | Buy | $32.3B | 198.44% | NA | -3.11% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $120.9B | 167.72% | 32.84 | -4.74% |
Insights on Cellectar Biosciences Inc
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 46.7%
In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 149.2%
AIGH Capital Management, LLC
Rosalind Advisors, Inc.
Nantahala Capital Management, LLC
Vanguard Group Inc
ADAR1 Capital Management LLC
Barclays PLC
cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p
Organization | Cellectar Biosciences Inc |
Employees | 20 |
CEO | Mr. James V. Caruso |
Industry | Health Technology |
A Spac I Acquisition Corp
$2.08
-0.95%
Keyarch Acquisition Corp
$2.08
-0.95%
Connexa Sports Technologies Inc
$2.08
-0.95%
Us Value Etf
$2.08
-0.95%
First Wave Biopharma Inc
$2.08
-0.95%
Global X Msci Next Emerging
$2.08
-0.95%
Fat Projects Acquisition Corp
$2.08
-0.95%
Capital Link Global Fintech
$2.08
-0.95%
Applied Uv Inc
$2.08
-0.95%